Clinical Trial Update: A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and effectiveness of hydroxyurea in patients on potent antiretroviral therapy with suppressed HIV RNA (<200 copies/mL).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• HYDROXYUREA (Hydroxyurea)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 2 | Status: COMPLETED